Class -Level and Drug -Level Persistence of IL-17Ai versus IL-23 Inhibitors in Psoriatic Arthritis: Results from the PPD CorEvitas PsA/SpA Registry (ACR Convergence 2026) - Sep 8, 2026 - Abstract #2288; Pres time: Nov 10, 2026; 10:30 AM - 12:30 PM; Location: WB1&2; In Person; "Secukinumab was initiated by the majority (66.5%) of the IL-17Ai cohort, and ixekizumab accounted for 33.5%. In the IL-23i cohort guselkumab accounted for 59.7%, while risankizumab accounted for 40.3% (Table 1)... Results from this observational study of pts with PsA, show that both IL-17Ai and IL-23i therapies had comparable persistence at M12. Results were consistent across drug-level and class-level analyses, suggesting that in PsA, IL-23 and IL-17 have similar persistence Figure 1. Kaplan-Meier plot of class-level persistence for PsA patients initiating an IL-17Ai and IL-23i in weighted cohorts."
Diabetes • Fibromyalgia • Immunology • Inflammatory Arthritis • Metabolic Disorders • Mood Disorders • Musculoskeletal Pain • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL17A • IL23A
|
|
Philip Mease 1; Nicole Middaugh 2; Maya Marchese 3; Skyler Peterson 4; Burcu Ertugrul Vardar 5; Russel Burge 5; Natalia Bello 5; Jill Zouzoulas 5; Marcus Ngantcha 6; Joseph Merola 7; Louis Bessette 8; and Alexis Ogdie 9
|